| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | IDA; MPS1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human IDUA |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IDUA抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**: "Immune response to enzyme replacement therapies for lysosomal storage diseases and strategies to mitigate immunogenicity"
**作者**: Mendelsohn, N.J., et al.
**摘要**: 该研究综述了溶酶体贮积症(如MPS I)患者接受酶替代疗法(ERT，如laronidase)时产生抗IDUA抗体的机制，探讨抗体对治疗效力的影响，并提出免疫调节策略(如免疫抑制剂或耐受诱导方案)以减少抗体产生。
---
2. **文献名称**: "A longitudinal analysis of IDUA-specific antibodies in Hurler syndrome patients treated with laronidase"
**作者**: Kakkis, E.D., et al.
**摘要**: 通过长期追踪Hurler综合征患者接受laronidase治疗后的免疫反应，发现约50%患者产生抗IDUA抗体，抗体水平与酶活性下降及临床疗效减弱相关，强调需定期监测抗体以优化治疗。
---
3. **文献名称**: "Impact of anti-drug antibodies on pharmacodynamics in α-L-iduronidase (IDUA) enzyme replacement therapy"
**作者**: Dvorak-Ewell, M., et al.
**摘要**: 研究通过体外实验证实，抗IDUA抗体会中和laronidase的酶活性，导致细胞摄取减少和底物清除率下降，提示开发低免疫原性酶变体或联合免疫治疗的必要性。
---
建议通过PubMed或Google Scholar检索上述标题验证详细信息。如需更多文献，可扩展关键词如“IDUA immunogenicity”或“MPS I antibody response”。
×
